Premier Laboratory Services, LLC

Premier Laboratory Services, LLC was paid $26.66M by Medicaid between Jan 2018 and Dec 2024, across 163 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 21% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Louisiana

Rank by total paid#3 of 66

Median peer was paid$253K

This provider vs. median106×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	339,350	$3.95M
2019	365,394	$4.62M
2020	135,165	$4.44M
2021	273,159	$6.61M
2022	135,412	$3.67M
2023	50,652	$2.25M
2024incomplete	39,004	$1.12M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	21%	165,576	47,710	$5.46M
0202U	Oncology (prostate), multianalyte, gene expression profiling	20%	14,908	13,497	$5.37M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	9.6%	34,854	19,169	$2.57M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	5.3%	11,625	7,803	$1.42M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.3%	41,677	19,756	$1.40M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.5%	138,521	34,199	$1.19M
80050	General health panel	2.5%	26,286	24,412	$659K
80348		1.0%	24,592	11,663	$268K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	15,895	14,472	$251K
80323		<1%	17,226	6,388	$247K
80373		<1%	24,902	11,730	$245K
80370		<1%	18,888	8,386	$241K

151 more codes

80347		<1%	19,449	$233K
84234		<1%	5,095	$221K
80364		<1%	18,925	$213K
80337		<1%	15,472	$205K
80372		<1%	20,246	$198K
80334		<1%	15,956	$198K
80354		<1%	24,264	$191K
83992		<1%	22,759	$190K
80361		<1%	23,158	$182K
80299		<1%	16,375	$181K
80325		<1%	17,835	$177K
80360		<1%	24,352	$177K
87486		<1%	9,258	$173K
87581		<1%	9,248	$173K
80368		<1%	18,710	$173K
80061	Lipid panel	<1%	24,293	$165K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	9,602	$162K
80356		<1%	21,716	$162K
87507		<1%	488	$161K
80358		<1%	22,131	$155K
80366		<1%	18,189	$152K
80365		<1%	20,048	$150K
80357		<1%	17,621	$147K
80359		<1%	21,689	$147K
80353		<1%	21,766	$145K
80321		<1%	17,329	$136K
80355		<1%	18,709	$135K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,408	$121K
80349		<1%	15,248	$116K
80338		<1%	5,927	$112K
82670		<1%	5,606	$103K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,362	$94K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,363	$94K
84439		<1%	14,934	$76K
82627		<1%	5,243	$76K
84481		<1%	10,352	$75K
84403		<1%	4,151	$68K
84146		<1%	5,277	$67K
80345		<1%	13,642	$66K
82607		<1%	6,676	$63K
83001		<1%	5,008	$61K
83002		<1%	4,937	$60K
80371		<1%	8,195	$56K
86803		<1%	5,648	$55K
83036	Hemoglobin; glycosylated (A1C)	<1%	12,105	$53K
83970		<1%	2,294	$53K
84443	Thyroid stimulating hormone (TSH)	<1%	9,142	$52K
84402		<1%	2,541	$48K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	13,638	$47K
82533		<1%	3,550	$41K
82746		<1%	4,423	$39K
80346		<1%	7,169	$39K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	418	$37K
80053	Comprehensive metabolic panel	<1%	9,572	$34K
84270		<1%	2,657	$32K
86376		<1%	2,955	$31K
83525		<1%	3,546	$30K
82728		<1%	4,458	$30K
80367		<1%	2,436	$30K
84153		<1%	3,609	$29K
80336		<1%	2,127	$29K
80375		<1%	2,246	$29K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	984	$27K
80362		<1%	3,690	$27K
87088		<1%	5,306	$25K
80324		<1%	3,462	$23K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,482	$23K
86705		<1%	2,744	$21K
86709		<1%	2,526	$19K
80369		<1%	1,496	$18K
80320		<1%	1,973	$18K
80333		<1%	1,287	$17K
83735		<1%	4,313	$17K
81001		<1%	7,713	$15K
86703		<1%	1,927	$14K
84702		<1%	1,827	$14K
83540		<1%	4,371	$13K
86706		<1%	2,150	$12K
80332		<1%	1,092	$12K
81002		<1%	7,506	$12K
83550		<1%	2,879	$12K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	863	$12K
83690		<1%	3,053	$12K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	4,512	$11K
82150		<1%	2,968	$11K
82043		<1%	3,059	$11K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,623	$11K
84550		<1%	3,886	$10K
83880		<1%	545	$9K
82977		<1%	2,651	$9K
80076		<1%	1,859	$8K
83090		<1%	1,437	$8K
86328		<1%	304	$7K
84466		<1%	1,351	$7K
86141		<1%	1,086	$7K
86702		<1%	973	$7K
86769		<1%	258	$7K
82550		<1%	1,706	$7K
86140		<1%	2,285	$6K
84100		<1%	2,243	$6K
87806		<1%	385	$6K
86701		<1%	970	$6K
84144		<1%	542	$5K
82570		<1%	1,814	$5K
85652		<1%	2,815	$5K
86431		<1%	1,444	$5K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	100	$4K
87632		<1%	21	$3K
86160		<1%	182	$3K
86800		<1%	405	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	97	$3K
82248		<1%	969	$2K
84436		<1%	1,639	$2K
87265		<1%	313	$2K
81003		<1%	1,631	$2K
85018		<1%	1,006	$2K
85014		<1%	1,004	$2K
82951		<1%	255	$2K
87498		<1%	96	$2K
87640		<1%	63	$2K
87541		<1%	62	$2K
82652		<1%	171	$2K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	2,673	$1K
87631		<1%	65	$1K
86708		<1%	218	$897.32
84480		<1%	1,059	$829.38
80335		<1%	47	$570.88
87503		<1%	94	$508.36
83721		<1%	1,378	$271.07
82530		<1%	18	$240.96
82947		<1%	146	$225.79
82310		<1%	53	$141.67
82950		<1%	37	$138.96
82247		<1%	59	$126.86
84484		<1%	14	$108.69
87040		<1%	12	$94.30
83570		<1%	16	$62.55
84479		<1%	97	$37.74
85610		<1%	16	$19.02
84450		<1%	60	$8.35
85027		<1%	61	$7.43
84075		0%	16	$0.00
84132		0%	13	$0.00
82040		0%	16	$0.00
82435		0%	13	$0.00
84460		0%	16	$0.00
84295		0%	13	$0.00
82374		0%	13	$0.00
84155		0%	16	$0.00
84520		0%	14	$0.00
82565		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBROUSSARD, VALERIE (OWNER / CFO)